Publications by authors named "Lisa A Kottschade"

Claim this Profile
C
Case Report: Complete pathologic response in advanced melanoma with SFRT and dual checkpoint inhibition.
Jared Hobson, Michael P Grams, Joanina K Gicobi, Dennis Wigle, Lisa A Kottschade

Front Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma.
Tina J Hieken, David Zahrieh, Thomas J Flotte, Roxana S Dronca, Evidio Domingo-Musibay, Lisa A Kottschade

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.
Ethan Basch, Deborah Schrag, Jennifer Jansen, Sydney Henson, Brenda Ginos, Lisa A Kottschade

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.
Matthew S Block, Garth D Nelson, Jun Chen, Stephen Johnson, Lu Yang, Lisa A Kottschade

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Social Determinants of Health on Melanoma Nodal Surveillance in a Multi-institutional Cohort.
Kelsey B Montgomery, M Chandler McLeod, Danielle K DePalo, Michelle M Dugan, Jonathan S Zager, Lisa A Kottschade

Ann Surg Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma exchange and radiation resensitize immunotherapy-refractory melanoma: a phase I trial.
Jacob J Orme, Henan Zhang, Prashanth Lingamaneni, Yohan Kim, Roxane Lavoie, Lisa A Kottschade

Nat Commun· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance Comparison of Liquid Chromatography and Paper Spray Ionization with Mass Spectrometry for Measuring Kinase Inhibitors in Human Plasma.
Richard G Lahr, Makenzie Meyer, Leah Nelson, Lisa A Kottschade, Paul J Jannetto

ACS Pharmacol Transl Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting.
Ronen Stoff, Svetomir N Markovic, Robert R McWilliams, Lisa A Kottschade, Heather N Montane

Melanoma Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Effect Duration of Immune Checkpoint Inhibitor-Related Pancreas Adverse Events.
Ferga C Gleeson, Katie A Dunleavy, Michael J Levy, Ryan M Carr, Mindy L Hartgers, Lisa A Kottschade

Pancreas· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies.
Eleftheria Kalogera, Wendy K Nevala, Heidi D Finnes, Vera J Suman, Jill M Schimke, Lisa A Kottschade

Clin Cancer Res· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Characterization of Immune Checkpoint Inhibitor-Induced Toxicities From Electronic Health Records Using Natural Language Processing.
Hannah Barman, Sriram Venkateswaran, Antonio Del Santo, Unice Yoo, Eli Silvert, Lisa A Kottschade

JCO Clin Cancer Inform· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
Ugur Sener, Mason Webb, William G Breen, Bryan J Neth, Nadia N Laack, Lisa A Kottschade

J Immunother Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.
Tina J Hieken, Garth D Nelson, Thomas J Flotte, Eric P Grewal, Jun Chen, Lisa A Kottschade

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.
John M Kirkwood, Lisa A Kottschade, Robert R McWilliams, Nikhil I Khushalani, Sekwon Jang

Immunotherapy· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses.
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, Adam J Weisbrod, Carrie A Strand, Lisa A Kottschade

Front Immunol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers.
Lisa A Kottschade, Casey Fazer-Posorske, Anna J Schwecke

Clin J Oncol Nurs· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma Methylated DNA Markers for Melanoma Surveillance.
Calise K Berger, William R Taylor, Douglas W Mahoney, Kelli N Burger, Karen A Doering, Lisa A Kottschade

JCO Precis Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay

Clin Cancer Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
Ethan Basch, Deborah Schrag, Sydney Henson, Jennifer Jansen, Brenda Ginos, Lisa A Kottschade

JAMA· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy.
Antoine N Saliba, Zhuoer Xie, Alexandra S Higgins, Xavier A Andrade-Gonzalez, Harry E Fuentes-Bayne, Lisa A Kottschade

Am J Hematol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.
Ethan Basch, Angela M Stover, Deborah Schrag, Arlene Chung, Jennifer Jansen, Lisa A Kottschade

JCO Clin Cancer Inform· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort.
Tina J Hieken, Amy E Glasgow, Elizabeth Ann L Enninga, Lisa A Kottschade, Roxana S Dronca

J Womens Health (Larchmt)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide vaccine with glucopyranosyl lipid A-stable oil-in-water emulsion for patients with resected melanoma.
Eric P Grewal, Courtney L Erskine, Wendy K Nevala, Jacob B Allred, Carrie A Strand, Lisa A Kottschade

Immunotherapy· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Jesus Vera Aguilera, Jonas Paludo, Robert R McWilliams, Henan Zhang, Ying Li, Lisa A Kottschade

Melanoma Res· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Thomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, Blake T Langlais, Aaron Mangold, Lisa A Kottschade

PLoS One· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis